On October 24, 2024, GSK plc reported promising data on their RSV vaccine, Arexvy, showing its efficacy in adults aged 18-49 with risk factors, with over 21 million in the U.S. potentially benefiting. The vaccine also demonstrated a good safety profile and induced robust immune responses comparable to older adults.